Endocrine Abstracts (2010) 22 P241

Macroprolactinoma after chronic buserelin treatment in patient with prostate cancer

Ferenc A Laszlo1, Mihály Gervain2, Erika Voros3, Andor H Molnár1 & Ferenc Laszlo1

1Department of Physiology, Anatomy and Neurosciences, University of Szeged, Szeged, Hungary; 2Department of Urology, City Hospital, Orosháza, Hungary; 3Department of Radiology, University of Szeged, Szeged, Hungary.

Twelve years following hemicolectomy for colon adenocarcinoma, a 75-year-old patient with prostate cancer was treated for 4 weeks with the antiandrogen nilutamide and then with the long-acting GnRH agonist buserelin. The serum testosterone and prostate-specific antigen (PSA) levels had decreased dramatically after 3 months of treatment. After 2 years of buserelin administration, the hormonal state was examined. Serum estradiol, testosterone, DHEA, DHEAS, FSH and LH levels proved to be suppressed, but the serum PRL concentration was extremely high (3 365 mIU/l). The pituitary MRI revealed a macroadenoma. The patient was treated with the dopamine agonist cabergoline, together with buserelin. After 5 months of this combined treatment, the PSA and testosterone levels were very low; the serum oestradiol, DHEA, DHEAS, FSH and LH concentrations remained suppressed. The serum PRL level fell dramatically to 6.95 mIU/l, and a reduction in tumor size was observed on MRI. In conclusion: Combined buserelin + cabergoline treatment proved a highly successful procedure to cure this patient with prostate carcinoma and subsequent pituitary macroprolactinoma.

Article tools

My recent searches

No recent searches.